A Deep Divide: Analysts Clash Over Abivax's Valuation

Analysts are split on Abivax, with targets from $110 to $175. A critical safety data readout this month could shift focus from M&A talk to clinical results.

A staggering $65 gap separates the price targets for Abivax, highlighting a fundamental disagreement on Wall Street about the biotechnology firm's worth. As a pivotal data readout approaches this month, the investment thesis is shifting from speculative takeover chatter to a focus on concrete clinical trial results.

The March Catalyst

The immediate focus for investors is a scheduled release of safety data for the company's lead drug candidate, obefazimod. Abivax's management has officially confirmed this data will be made public before the end of March. According to analysts at Guggenheim, these results are a critical near-term catalyst that could validate their bullish stance.

However, this safety review is merely the initial phase of a longer regulatory pathway. The company's management is already looking ahead to mid-2026, when results from a 44-week maintenance study are expected. That later trial will ultimately determine the drug's final approval prospects and its long-term commercial potential.

A Tale of Two Price Targets

The analyst community is sharply divided. On one side, Wedbush has initiated coverage with an "Underperform" rating, issuing a cautious price target of $110. Their analysts warn that expectations for near-term merger or acquisition activity are overly optimistic and carry significant risk.

In the opposing camp, Guggenheim reaffirms a "Buy" recommendation with a substantially higher price target of $175. Their optimism is rooted in anticipated strategic developments that could be imminent. The contrasting views are clear:

• Guggenheim: "Buy," $175 price target
• Wedbush: "Underperform," $110 price target

Positive safety data this month could potentially strengthen the fundamental investment case and mitigate some of the skepticism surrounding merger speculation. The coming days are likely to bring clarity, as the market digests this new clinical information and begins to judge which analyst outlook is more accurate.